Robert W Cross
Overview
Explore the profile of Robert W Cross including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
2901
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woolsey C, Cross R, Chu V, Prasad A, Agans K, Borisevich V, et al.
Sci Adv
. 2025 Mar;
11(11):eadw0659.
PMID: 40085692
Obeldesivir (ODV; GS-5245) is an orally administered ester prodrug of the parent nucleoside GS-441524 that has broad spectrum antiviral activity inhibiting viral RNA-dependent RNA polymerases. We recently showed that ODV...
2.
Johnson D, Fenton K, Dobias N, Geisbert T, Cross R
J Infect Dis
. 2025 Feb;
PMID: 39980339
Chapare virus (CHAPV) is an emerging arenavirus first discovered in Bolivia. Clinical cases have a high case fatality rate and a concerning capacity for person-to-person spread. Animal models of CHHF...
3.
Cross R, Woolsey C, Prasad A, Borisevich V, Agans K, Deer D, et al.
Nat Med
. 2025 Jan;
PMID: 39805309
The recent outbreak of Marburg virus (MARV) in Rwanda underscores the need for effective countermeasures against this highly fatal pathogen, with case fatality rates reaching 90%. Currently, no vaccines or...
4.
Woolsey C, Geisbert T, Cross R
Methods Mol Biol
. 2024 Nov;
2877:297-315.
PMID: 39585629
Marburg virus (MARV) has caused sporadic outbreaks of severe hemorrhagic fever in Africa in humans and nonhuman primates (NHPs) and has the potential to be used as a biological weapon....
5.
Cross R
Methods Mol Biol
. 2024 Nov;
2877:281-295.
PMID: 39585628
Filoviruses, including Ebola and Marburg viruses, have caused periodic outbreaks of severe hemorrhagic disease in humans and nonhuman primates (NHP), resulting in major public health emergencies primarily in endemic areas....
6.
Massey C, Cross R, Woolsey C
Methods Mol Biol
. 2024 Nov;
2877:239-257.
PMID: 39585626
Various animal models have been established to gain a better understanding of the pathogenesis of Marburg virus (MARV) and Ravn virus (RAVV), and to develop medical countermeasures (MCMs) against them....
7.
Zeitlin L, Cross R, Woolsey C, West B, Borisevich V, Agans K, et al.
Sci Transl Med
. 2024 Apr;
16(741):eadl2055.
PMID: 38569014
No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra virus (HeV) G glycoprotein,...
8.
Cross R, Woolsey C, Chu V, Babusis D, Bannister R, Vermillion M, et al.
Science
. 2024 Mar;
383(6688):eadk6176.
PMID: 38484056
Obeldesivir (ODV, GS-5245) is an orally administered prodrug of the parent nucleoside of remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. In this work, we show...
9.
Cross R, Fenton K, Woolsey C, Prasad A, Borisevich V, Agans K, et al.
Cell Rep Med
. 2024 Jan;
5(2):101392.
PMID: 38280377
Lassa fever (LF) is an acute viral illness that causes thousands of deaths annually in West Africa. There are currently no Lassa virus (LASV) vaccines or antivirals approved for human...
10.
Woolsey C, Cross R, Prasad A, Agans K, Borisevich V, Deer D, et al.
Emerg Microbes Infect
. 2024 Jan;
13(1):2301061.
PMID: 38164768
Lassa virus (LASV) is a World Health Organization (WHO) priority pathogen that causes high morbidity and mortality. Recently, we showed that a combination of three broadly neutralizing human monoclonal antibodies...